Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET) Academic Article uri icon

Overview

MeSH Major

  • Angiotensin-Converting Enzyme Inhibitors
  • Heart Failure
  • Quinolines

abstract

  • These results indicate that additional symptomatic benefit can be attained by adding flosequinan to a therapeutic regimen already including a converting enzyme inhibitor. Because in the future most patients will fall into this category, flosequinan is a potential adjunctive agent in the management of severe congestive heart failure. However, because recent evidence indicates that the flosequinan dose studied in the present trial has an adverse effect on survival, the benefit-to-risk ratio must be assessed in individual patients.

publication date

  • January 1993

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8339411

Additional Document Info

start page

  • 492

end page

  • 501

volume

  • 88

number

  • 2